Nemes Rush Group
ALNY icon

Nemes Rush Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nemes Rush Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.23K Hold
5
– – ﹤0.01% 819
2026
Q2 		$1.5K Hold
5
– – ﹤0.01% 820
2026
Q1 		$1.65K Hold
5
– – ﹤0.01% 772
2025
Q4 		$1.99K Buy
+5
New +$2.21K ﹤0.01% 734

Other funds holding ALNY

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Nemes Rush Group's ALNY Position: Q3 2026 in Review

Nemes Rush Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2026 at 5 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #819.

Nemes Rush Group first reported a position in ALNY in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.99K in Q4 2025. 328 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Nemes Rush Group held 5 shares of Alnylam Pharmaceuticals worth $1.23K as of Q3 2026.
  • Nemes Rush Group left its Alnylam Pharmaceuticals share count unchanged in Q3 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #819 holding.
  • Nemes Rush Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Nemes Rush Group's Alnylam Pharmaceuticals position peaked at $1.99K in Q4 2025.
  • 328 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.